Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy

Antiviral Therapy

Volumn 3, Issue 4, 1998, Pages 215-220

  Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD LEVEL; DRUG COMBINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; TREATMENT PLANNING; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 0032447719     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakowitz JA & Fischl MA for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337:725-733.
2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini E & Chodakowitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997; 337: 734-739.
3. Rozenbaum W, Adda N, Wirbele E, Hadacek B, Schneider V & Costagliola D. Predictors and incidence of failure in 500 advanced stage HIV patients treated with indinavir. Fifth Conference on Retroviruses and Opportunistic Infections, 1-5 February 1998, Chicago, USA. Abstract 420.
4. Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, Wieland U, Pfister H, Reiser M, Hegener P, Franzen C, Schwenk A & Salzberger B. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11:F113-116.
5. Vanhove GF, Schapiro JM, Winters MA, Merigan TC & Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. Journal of the American Medical Association 1996; 276:1955-1956.
6. Anonymous: Guidelines for the use of antiretroviral agents in-HIV-infected adults and adolescents. Developed by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Version November 1997. http://www.cdcnac.org
7. Burger DM, De Graaff M, Wuis EW, Koopmans PP & Hekster YA. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography Biomedical Applications 1997; 703:235-241.
8. Anonymous: Crixivan™ product monograph. Merck & Co., Inc., August 1997.
9. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL & Drusano GL. A 24-week open-label phase I/II evaluation of the HIV-protease inhibitor MK-639 (indinavir). AIDS 1996; 10:485-492.
10. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ & Merigan TC. The effect of high dose saquinavir on viral load and CD4+ cell counts in HIV-infected patients. Annals of Internal Medicine 1996; 124:1039-1050.
11. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CAB, Leonard JM, Norbeck DW & Kempf DJ. Ordered accumulation of mutations in HIV-protease confers resistance to ritonavir. Nature Medicine 1996; 2:760-766.
12. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4:171-184.
13. Chiba M, Hensleigh M, Nishime JA, Balani SK & Lin JH. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metabolism and Disposition 1996; 24:307-314.
14. Burger DM, Hoetelmans RMW, Koopmans PP, Meenhorst PL, Mulder JW, Hekster YA & Beijnen JH. Clinically relevant drug interactions with antiretroviral agents. Antiviral Therapy 1997; 2:149-165.